posted
Breaking...really nice news yesterday that took a bit to hit.
CT Laser Mammography Study Featured in Prominent Peer-Reviewed Journal
Tuesday , July 05, 2005 09:40 ET
FORT LAUDERDALE, Fla., July 5, 2005 /PRNewswire-FirstCall via COMTEX/ --Imaging Diagnostic Systems, Inc. (OTC Bulletin Board: IMDS) announced today that a study demonstrating the potential of CTLM to characterize benign and malignant tumors was featured in the June issue of "Investigative Radiology."
The study, conducted by the Department of Radiology and the Department of Gynecology and Obstetrics at the Medical University of Vienna, Austria, analyzed 105 breast lesions discovered in 100 women through x-ray mammography. Lesions were investigated through CTLM images and additional mammograms. In the evaluation of each lesion, CTLM images and mammograms were interpreted without the information provided by the other modality. Histologic analysis was used to verify the results.
A significant correlation was observed between absorption of laser light as seen on CTLM scans and the presence of malignant breast tumors. Absorption was seen more often in more aggressive cancers, which seem to develop more new blood vessels than less aggressive cancers. Researchers were also able to gain information about the shape and appearance of both benign and malignant tumors through the images obtained from CTLM scans.
"We observed that CTLM was able to visualize the majority of malignant lesions in our study. Thus, we believe that optical mammography is a promising technology, which warrants further investigation," stated Dr. Daniel Flory of the Department of Radiology.
"Investigative Radiology" features studies conducted and evaluated by researchers throughout the world. The journal covers a range of radiological topics from diagnostic imaging and the use of radioactive isotopes to modalities such as computed tomography, positron emission tomography, magnetic resonance imaging, and ultrasound.
The CTLM(R) system is the first patented breast imaging system that utilizes state-of the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking Premarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.
Please visit Imaging Diagnostic Systems' website at http://www.imds.com for additional information.
In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc. is included in the Company's filing with the Securities Exchange Commission.
Investor Relations: Rick Lutz 404-261-1196 lcgroup@mindspring.com
SOURCE Imaging Diagnostic Systems, Inc.
Investor Relations, Rick Lutz, +1-404-261-1196, or lcgroup@mindspring.com, for Imaging Diagnostic Systems
http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
